You are viewing a single comment's thread from:
RE: Research News: Potential Cancer Treatments Through Inhibiting HER Kinase
I previously worked with erlotinib, a chemotherapeutic EGFR (HER1) inhibitor. Of course genetic variance in tumors is very important for the response to a drug - that's why this work is exceptional.
But from what I understood, a main problem of RTK inhibitors is the quite fast development of tumor resistance.
Too-lazy-to-use-pubmed-question: Do you have any idea if the aquiration of resistance was yet connected to certain genes or mutations?
The development of resistances is definitely due to mutations ( that's how the process works, as I'm sure you are aware). Unfortunately I am not knowledgeable on the specifics of mutational prevalence of the resistant variants.
I think DNA methylation (or loss of methylation), especially in promoter regions of ABC transporters, also plays a role.
However, it would be nice to find genetic prevalence not only for response, but also for resistance! Ty for your answer.